314 related articles for article (PubMed ID: 33843859)
1. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
Bal S; Costa LJ
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
[TBL] [Abstract][Full Text] [Related]
2. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
3. Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph.
Wolf J; Fonseca R; Muffly L
Clin Adv Hematol Oncol; 2020 Mar; 18 Suppl 9(3):1-16. PubMed ID: 33843875
[TBL] [Abstract][Full Text] [Related]
4. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
5. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
Derman BA; Fonseca R
Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
[TBL] [Abstract][Full Text] [Related]
6. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
Ho C; Syed M; Roshal M; Petrova-Drus K; Moung C; Yao J; Quesada AE; Benhamida J; Vanderbilt C; Liu Y; Zhu M; Yu W; Maciag L; Wang M; Ma Y; Gao Q; Rustad EH; Hultcrantz M; Diamond BT; Zheng-Lin B; Huang Y; Hutt K; Miller JE; Dogan A; Nafa K; Landgren O; Arcila ME
J Mol Diagn; 2021 Feb; 23(2):181-199. PubMed ID: 33217553
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
8. Molecular Diagnostics of Plasma Cell Neoplasms.
Fitzpatrick MJ; Murali MR; Nardi V
Surg Pathol Clin; 2023 Jun; 16(2):401-410. PubMed ID: 37149365
[TBL] [Abstract][Full Text] [Related]
9. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
10. Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma.
Cho H; Shin S; Chung H; Jang JE; Kim YR; Cheong JW; Min YH; Lee ST; Choi JR; Kim JS
Br J Haematol; 2022 Aug; 198(3):503-514. PubMed ID: 35505579
[TBL] [Abstract][Full Text] [Related]
11. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
12. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
13. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
Stetler-Stevenson M; Paiva B; Stoolman L; Lin P; Jorgensen JL; Orfao A; Van Dongen J; Rawstron AC
Cytometry B Clin Cytom; 2016 Jan; 90(1):26-30. PubMed ID: 25907102
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of minimal residual disease detection in multiple myeloma].
Takamatsu H
Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
[TBL] [Abstract][Full Text] [Related]
16. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
Rustad EH; Boyle EM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
[TBL] [Abstract][Full Text] [Related]
17. Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum.
Tapia-Alveal C; Olsen TR; Worgall TS
Commun Biol; 2020 Dec; 3(1):781. PubMed ID: 33335255
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
19. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma.
Medina A; Jiménez C; Puig N; Sarasquete ME; Flores-Montero J; García-Álvarez M; Prieto-Conde I; Chillón C; Alcoceba M; González-Calle V; Gutiérrez NC; Jacobsen A; Vigil E; Hutt K; Huang Y; Orfao A; González M; Miller J; García-Sanz R
Arch Pathol Lab Med; 2022 Jul; 146(7):862-871. PubMed ID: 34619755
[TBL] [Abstract][Full Text] [Related]
20. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.
Gozzetti A; Bocchia M
Rev Recent Clin Trials; 2022; 17(1):9-10. PubMed ID: 34814822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]